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Abstract
Introduction: The endocannabinoid system participates in food intake, energy
balance and lipid and glucose metabolism. The biological effects of cannabinoids
are limited by the activation of the endocannabinoid degrading enzyme fatty
acid amide hydrolase (FAAH). This study aims to analyse whether 385 C/A
polymorphism of FAAH is associated with metabolic syndrome (MetS) in the
Chinese Han population. 
Material and methods: A total of 112 subjects at risk for MetS and 80 healthy
controls from Fuzhou, China were genotyped for 385 C/A polymorphism of FAAH
using TaqMan assay. Anthropometric measurements and biochemical asses  -
sments such as BMI, waist circumference, blood pressure, serum triglycerides
(TG), serum total cholesterol, high-density lipoprotein-cholesterol, low-density
lipoprotein-cholesterol, fasting plasma glucose, and plasma insulin levels were
performed.
Results: CA and AA genotypes of FAAH had higher incidence in MetS subjects
than in control subjects. CA and AA genotypes of FAAH in subjects with MetS
had relatively elevated levels of waist circumference, body mass index,
homeostasis model assessment of insulin resistance (HOMA-IR) and serum
triglycerides, and lowered level of high-density lipoprotein cholesterol (HDL-c)
compared with CC genotype in MetS subjects. 
Conclusions: Results suggest that 385 C/A polymorphism of the FAAH gene may
confer an increased risk of MetS in the Chinese Han population.
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Introduction
Metabolic syndrome (MetS) is characterized by multiple compounding
factors such as abdominal obesity, insulin resistance, elevated serum
triglyceride (TG) levels, low high-density lipoprotein cholesterol (HDL-c)
levels and high blood pressure [1]. Many susceptibility genes have been
shown to contribute to the susceptibility of developing MetS [2].
The endocannabinoid system plays an important role in the regulation
of food consumption and energy balance; it also influences the regulation
of lipid and glucose metabolism [3]. The main enzyme that inactivates the
endocannabinoid is fatty acid amide hydrolase (FAAH), which has been
identified as a catabolic enzyme capable of degrading most of the
endocannabinoids [4]. The endocannabinoid level was significantly elevated
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Copyright © 2011 Termedia & Banachin mice lacking FAAH, which indicates that FAAH is
a key regulator of endocannabinoid signalling [5].
A common C > A single nucleotide polymorphism
(SNP) resulting in a missense mutation (385C > A)
has been described previously. An association of
the mutant genotype of FAAH with a worse
cardiovascular profile, such as increased weight,
body mass index (BMI), waist circumference (WC),
insulin and TNF-α levels, and decreased adiponectin
levels was also observed [6]. This study suggests
that FAAH plays a great role in the metabolic
aspects of feeding behaviour and body weight. 
Although studies have focused on the
association of the C385A polymorphism of FAAH
with obesity and diabetes, an investigation on the
association of this polymorphism with MetS has
not been performed yet. Therefore, this study aims
to analyse whether 385 C/A polymorphism of FAAH




A total of 112 MetS subjects undergoing an
annual physical examination in the outpatient
department of Union Hospital, Fujian Medical
University were enrolled in this study. Metabolic
syndrome was defined using the criteria established
in the third report of the National Cholesterol
Education Program Expert Panel on Detection,
Evaluation, and Treatment in the Asian population
(Adult Treatment Panel III) as the presence of 3 or
more of the following risk factors [7]: WC ≥ 80 cm
in women or ≥ 90 cm in men, TG ≥ 1.69 mmol/l,
HDL-c ≤ 1.29 mmol/l in women or ≤ 1.03 mmol/l in
men, systolic blood pressure (SBP) ≥ 130 mmHg
and/or diastolic blood pressure (DBP) ≥ 85 mmHg,
fasting blood glucose (FBG) ≥ 5.6 mmol/l. 
Normal subjects (n = 80) who entered the
healthy evaluation programme were assigned as
the control group for this study. These subjects had
none of the five criteria of MetS described above
and no history of obesity, dyslipidaemia, hyper  -
tension, or diabetes mellitus. This study was
approved by the ethics committee of our hospital,
and informed consent was obtained from all
participants.
Measurements 
Anthropometric (height, weight, WC and blood
pressures) and laboratory analyses were performed.
Fasting plasma glucose, serum TG, total cholesterol
(TC), HDL-c and low-density lipoprotein cholesterol
(LDL-c) were detected using an auto biochemistry
instrument (LX20, BECMAN, CA, USA). Plasma
fasting insulin level was measured by radio  -
immunoassay (RIA Diagnostic Corporation, Los
Angeles, CA). Body mass index was calculated as
weight in kilograms divided by the square of height
in metres (kg/m2). The homeostasis model asses  -
sment of insulin resistance (HOMA-IR) was calculated
as the insulin reading (μIU/ml) multiplied by plasma
glucose level (mmol/l) and divided by 22.5.
DNA genotyping
Venous blood of all subjects was collected and
frozen immediately at –20°C until the extraction of
genomic DNA from nucleated white blood cells.
DNA was isolated from 200 ml of anticoagulated
peripheral blood using a commercially available kit
according to the manufacturer’s instructions
(QIAamp DNA Blood Mini Kit, QIAGEN Inc, CA, USA).
The 385 C/A polymorphism of the FAAH gene was
determined using the TaqMan SNP Genotyping
Assays on ABI 7900 (Applied Biosystems, Foster
City, CA, USA). As a standard laboratory quality
control measure, 10% of DNA samples were
randomly selected and systematically re-
genotyped. A concordance rate of 100% was
recorded for this SNP .
Statistical analysis
Data are displayed as means ± standard
deviation (SD). Student’s t-test was performed to
compare biochemical variables between the MetS
and control group. χ2 and p values for FAAH 385 C/A
genotypes among MetS patients and controls were
calculated using an online χ2 test. The different
variables of FAAH genotypes among MetS patients
Characteristics MetS Control  Value of p
groupg roup
Age [years] 60.04 ±9.46 57.98 ±10.19 0.150
Gender (M/F) 65/47 45/35 0.805
WC [cm] 84.63 ±10.05 78.36 ±7.82 < 0.001
BMI [kg/m2] 27.06 ±3.86 24.19 ±2.45 < 0.001
SBP [mmHg] 142.13 ±12.74 123.81 ±14.34 < 0.001
DBP [mmHg] 84.42 ±9.58 82.00 ±8.97 0.078
HOMA-IR 2.48 ±0.77 1.56 ±0.48 < 0.001
TG [mmol/l] 1.80 ±0.85 1.07 ±0.51 < 0.001
TC [mmol/l] 5.13 ±1.12 5.15 ±0.89 0.910
HDL-c [mmol/l] 1.13 ±0.24 1.41 ±0.22 < 0.001
LDL-c [mmol/l] 3.35 ±0.83 3.24 ±0.58 0.468
Table I. Comparison of anthropometric and biological
parameters between MetS patients and control
subjects
Values are given as mean ± SD.
MetS – metabolic syndrome, WC – waist circumference, BMI – body
mass index, SBP – systolic blood pressure, DBP – diastolic blood
pressure, HOMA-IR – homeostasis model assessment of insulin
resistance, TG – triglycerides, TC – total cholesterol, HDL-c – high-density
lipoprotein cholesterol, LDL-c – low-density lipoprotein cholesterol
424 Arch Med Sci 3, June / 2011
JinYang Zeng, JianRong Li, GuoLiang HuangArch Med Sci 3, June / 2011 425
Polymorphism of FAAH gene is associated with metabolic syndrome
were analysed using Student’s t-test. The normality
of distributions of the variables was tested by the
Kolmogorov-Smirnov (KS) test. A p value under 0.05
was considered statistically significant.
Results
The anthropometric and biological parameters
of the MetS patients and the control subjects are
presented in Table I. The MetS group showed higher
levels of WC, BMI, SBP, HOMA-IR and serum TG and
a lowered HDL-c level compared with the control
group. No significant differences were observed in
age, gender, DBP, serum TC and LDL-c levels
between the two groups. 
Genotype and allele frequencies of the FAAH
gene in MetS subjects and healthy controls are
listed in Table II. A significantly different allelic
distribution of FAAH gene polymorphism was found
between the two groups. A greater proportion of
the CA and AA genotypes and a lower proportion
of the CC genotype were observed in the MetS
group compared with the healthy controls. 
Patients with the CC genotype had significantly
lower levels of WC, BMI, HOMA-IR and serum TG,
and increased HDL-c levels than those with the CA
and AA genotypes in the MetS group. No significant
differences were found in SBP, DBP, serum TC and
LDL-c levels between the mutant-type group and
wild-type group. The characteristics of the different
genotypes of the FAAH 385 C/A polymorphism in
MetS subjects are presented in Table III.
Discussion
The present study suggests that the FAAH gene
may constitute a predisposing factor to MetS.
Previous studies have described the association of
this polymorphism with obesity and lipid metabolism.
However, there is no comprehensive investigation
about the possible role of this polymorphism in the
development of MetS. In our study, a greater
proportion of the CA and AA genotypes, and
a smaller proportion of the CC genotype, were found
in the MetS patients compared with the healthy
group. Our results reveal that the FAAH gene may be
an important candidate gene of MetS. 
The possible association between the 385 C/A
polymorphism of the FAAH and MetS can be
explained by the biological role of FAAH. The
endocannabinoid system plays an important role
in the hypothalamic and peripheral regulation of
food intake, obesity and metabolism. Fatty acid
amide hydrolase serves as a key enzyme in the
endocannabinoid degra  dation pathway by
degrading most of the endocannabinoids [8].
Therefore, it is plausible to hypothesize that
mutation in the FAAH gene may cause decreased
expression or activity of FAAH. This leads to
increased stimulation of the endocannabinoid
receptor and thereby results in increased food
intake and body fat accumulation. Significantly
elevated levels of the endocannabinoid were found
in subjects with the mutant-type of the FAAH gene
than in those with wild-type controls, which
indicated that the endocannabinoid system
activation may be due to the effect of the FAAH
mutant genotype on the plasma endocannabinoid
levels [9]. FAAH–/– mice showed boosted energy
storage compared with their wild-type littermates
[10]. These results suggest the possible role of FAAH
in the regulation of food intake and energy balance.
Previous studies have shown the association
between the 385 C/A polymorphism of FAAH and
obesity. The homozygous FAAH 385 A/A genotype
was significantly associated with overweight and
obesity in white subjects and in black subjects but
not in a small group of Asians [11]. An association
of the FAAH variants at the early onset of obesity
was also observed [12]. An elevated level of adipose
Group n Genotype Allele
CC CAA A C A
MetS 112 68 (60.7%) 40 (35.7%) 4 (3.6%) 78.6% 21.4%
Control 80 63 (78.8%) 16 (20.0%) 1 (1.2%) 88.8% 11.2%
Table II. Genotype and allele frequencies of the 385 C/A polymorphism of FAAH between MetS subjects and control
subjects
Pearson χ2 value = 8.567, p = 0.014, n – sample number, other abreviations – see table I
Characteristics CC CA + AA Value of p
WC 82.94 ±10.68 87.23 ±8.44 0.020
BMI 26.34 ±3.82 28.17 ±3.69 0.014
SBP 141.69 ±11.45 142.80 ±14.64 0.673
DBP 84.63 ±9.28 84.09 ±10.13 0.772
HOMA-IR 2.34 ±0.74 2.68 ±0.79 0.023
TG 1.67 ±0.84 2.02 ±0.83 0.033
TC 5.06 ±1.21 5.24 ±0.97 0.409
HDL-c 1.16 ±0.26 1.07 ±0.18 0.043
LDL-c 3.29 ±0.89 3.34 ±0.72 0.721
Table III. Comparison of characteristics of different
genotypes of FAAH gene in subjects with MetS
Values are given as mean ± SD, abbreviations – see table I426 Arch Med Sci 3, June / 2011
FAAH was shown to be significantly associated with
a decrease in food intake in C3H mice [13]. These
findings indicate that FAAH variants may be
involved in the aetiology of obesity. Similarly, the
results of this study also demonstrate that WC and
BMI were increased more in the mutant-type group
than in the wild-type group.
The present study demonstrates that the level
of HOMA-IR was significantly elevated in the
subjects carrying A allele in comparison with the
wild control subjects, indicating the possible
involvement of FAAH in the development of insulin
resistance. Similar results were also reported by
other studies. Compared with the controls, FAAH–/–
mice showed increased plasma insulin and blood
glucose levels, leading to enhanced insulin
resistance [10]. A higher plasma insulin level was
found in the mutant-type group than in the wild-
type group [6]. However, another study reported
that insulin, glucose and HOMA levels are elevated
more in the wild-type group than in the mutant-
type group [14]. This discrepancy may have resulted
from the environmental and ethnic differences
between the populations or the differences in
sample collection and storage. 
This study suggests that the mutant genotype of
the FAAH gene in subjects with MetS had more
elevated TG levels and lower HDL-c concentrations
than the wild genotype. Previous evidence suggests
that FAAH may be involved in the pathogenesis of
dyslipidaemia. The 385 C/A polymorphism of the
FAAH gene was found to be associated with
increased serum TG and reduced levels of HDL-c [15].
Plasma free fatty acids and TG concentrations were
significantly increased in FAAH–/– mice compared to
the normal littermates [10]. These results suggest
a possible involvement of FAAH activation in the
metabolism of obesity-related hypertriglyceridaemia
and predict the potential efficacy of cannabinoid
antagonists in treating metabolic diseases.
A previous study suggests that young male
subjects carrying the FAAH variant have relatively
lower blood pressure [16]. We compared the SBP
and the DBP between the MetS subjects from the
wild-type and those from the mutant-type group.
Blood pressure was not correlated with this
polymorphism, a finding that is distinct from the
study of Sarzani [16]. No significant relationship of
blood pressure with the 385 C/A polymorphism of
FAAH was also reported by several other
investigators [6, 17]. This inconsistency may be
attributed to the complex interactions between
multiple population-specific genetic factors as well
as environmental factors.
The potential limitations of these data merit
consideration. First, this cross-sectional study has
a relatively small population size. Therefore, it is
necessary to validate our data in prospective
studies with a larger population size. Second, as our
study was conducted in a sample of Chinese
patients, extrapolation of the data to other ethnic
groups should be done with great caution.
In conclusion, this study indicates that the 385
C/A polymorphism of the FAAH gene may be a risk
factor for susceptibility to MetS. Thus, people with
this polymorphism who are at a high risk for MetS
should take necessary precautions such as doing
more exercises and eating healthy food to prevent
or delay the development of MetS. This finding may
support the therapeutic use of cannabinoid
antagonist strategies. 
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